Fol. Biol. 2017, 63, 146-154
https://doi.org/10.14712/fb2017063040146
Expression of c-MET Protein in Various Subtypes of Hepatocellular Adenoma Compared to Hepatocellular Carcinoma and Non-Neoplastic Liver in Human Tissue
References
1. 2015) Hepatocellular adenoma with malignant transformation in male patients with non-cirrhotic livers. Chin. J. Cancer 34, 217-224.
< , S. L., Wang, L. M., Rong, W. Q., Wu, F., Sun, W., Yu, W. B., Feng, L., Liu, F. Q., Tian, F., Wu, J. X. (https://doi.org/10.1186/s40880-015-0014-x>
2. 2012) Genetic alterations in colorectal cancer. Gastrointest. Cancer Res. 5, 19-27.
, T., Wilson, J. D., Chu, Q., Mills, G. (
3. 2012) Hepatocellualar carcinoma serum markers. Semin. Oncol. 39, 410-433.
< , G., Ardiri, A., Malaguarnera, M., Malaguarnera, G., Bertino, N., Calvagno, G. S. (https://doi.org/10.1053/j.seminoncol.2012.05.001>
4. 2007) Pathological diagnosis of liver cell adenoma and focal nodular hyperplasia: Bordeaux update. J. Hepatol. 46, 521-527.
< , P., Balabaud, C., Bedossa, P., Scoazec, J. Y., Chiche, L., Dhillon, A. P., Ferrell, L., Paradis, V., Roskams, T., Vilgrain, V., Wanless, I. R., Zucman-Rossi, J., Laennec, Elves, G. (https://doi.org/10.1016/j.jhep.2006.12.007>
5. 2000) Estrogens as endogenous genotoxic agents – DNA adducts and mutations. J. Natl. Cancer Inst. Monogr. 27, 75-93.
< , E., Frenkel, K., Liehr, J. G., Rogan, E., Roy, D. (https://doi.org/10.1093/oxfordjournals.jncimonographs.a024247>
6. 2016) EGFR family and cMet expression profiles and prognostic significance in esophagogastric adenocarcinoma. J. Gastrointest. Oncol. 7, 838-847.
< , E., Alkhasawneh, A., Duckworth, L. V., Aijaz, T., Toro, T. Z., Lu, X., Hughes, S. J., Collinsworth, A., George, T. J., Jr. (https://doi.org/10.21037/jgo.2016.06.09>
7. 2013) β-catenin overexpression in the nucleus predicts progress disease and unfavourable survival in colorectal cancer: a meta-analysis. PLoS One. 8, e63854.
< , Z., He, X., Jia, M., Liu, Y., Qu, D., Wu, D., Wu, P., Ni, C., Zhang, Z., Ye, J., Xu, J., Huang, J. (https://doi.org/10.1371/journal.pone.0063854>
8. 2013) Expression and prognostic value of VEGFR-2, PDGFR-β and c-Met in advanced hepatocellular carcinoma. J. Exp. Clin. Cancer Res. 32, 16.
< , J. S., Ge, F. J., Zhang, B., Wang, Y., Silvestris, N., Liu, L. J., Zhao, C. H., Lin, L., Brunetti, A. E., Fu, Y. L., Wang, J., Paradiso, A., Xu, J. M. (https://doi.org/10.1186/1756-9966-32-16>
9. 1976) Livercell adenomas associated with use of oral contraceptives. N. Engl. J. Med. 294, 470-472.
< , H. A., Henderson, B., Benton, B. (https://doi.org/10.1056/NEJM197602262940904>
10. 2011) Changing trends in malignant transformation of hepatocellular adenoma. Gut 60, 85-89.
< , O., Ferreira, N., Dokmak, S., Belghiti, J., Bedossa, P., Paradis, V. (https://doi.org/10.1136/gut.2010.222109>
11. 2015) c-MET expression in colorectal adenomas and primary carcinomas with its corresponding metastases. J. Gastrointest. Oncol. 6, 618-627.
, M. F., Abd El-Maqsoud, N. M., El-Hameed El-Heeny, A. A., Mohammed, M. F. (
12. 2014) Met as a therapeutic target in HCC: facts and hopes. J. Hepatol. 60, 442-452.
< , S., Columbano, A. (https://doi.org/10.1016/j.jhep.2013.09.009>
13. 2012) Integrated analysis of somatic mutations and focal copy-number changes identifies key genes and pathways in hepatocellular carcinoma. Nat. Genet. 44, 694-698.
< , C., Amaddeo, G., Imbeaud, S., Ladeiro, Y., Pelletier, L., Maad, I. B., Calderaro, J., Bioulac-Sage, P., Letexier, M., Degos, F., Clement, B., Balabaud, C., Chevet, E., Laurent, A., Couchy, G., Letouze, E., Calvo, F., Zucman- Rossi, J. (https://doi.org/10.1038/ng.2256>
14. 2011) Genetics and imaging of hepatocellular adenomas: 2011 update. Radiographics 31, 1529-1543.
< , V. S., Menias, C. O., Shanbhogue, A. K., Jagirdar, J., Paspulati, R. M., Prasad, S. R. (https://doi.org/10.1148/rg.316115527>
15. 2009) A case of hepatocellular carcinoma within hepatocellular adenoma in a non-cirrhotic male. Korean J. Intern. Med. 24, 147-152.
< , D. H., Kim, S. U., Nam, D. H., Choi, Y. J., Park, S. M., Lee, C. K., Kim do, Y. (https://doi.org/10.3904/kjim.2009.24.2.147>
16. 2002) Malignant transformation of hepatic adenoma with recurrence after resection. HPB (Oxford) 4, 139-143.
< , K. A., Weber, S. M., Fong, Y., Blumgart, L. H. (https://doi.org/10.1080/136518202760388055>
17. 2013) A survey of c-MET expression and amplification in 287 patients with hepatocellular carcinoma. Anticancer Res. 33, 5179-5186.
, S. J., Lee, J., Sohn, I., Mao, M., Kai, W., Park, C. K., Lim, H. Y. (
18. 2003) Hepatocellular carcinoma. Lancet 362, 1907-1917.
< , J. M., Burroughs, A., Bruix, J. (https://doi.org/10.1016/S0140-6736(03)14964-1>
19. 2007) Lung cancer cell lines harboring MET gene amplification are dependent on Met for growth and survival. Cancer Res. 67, 2081-2088.
< , B., Zeng, Q., Davis, L. J., Hatch, H., Hang, G., Kohl, N. E., Gibbs, J. B., Pan, B. S. (https://doi.org/10.1158/0008-5472.CAN-06-3495>
20. 2016) Hepatocellular adenoma classification: a comparative evaluation of immunohistochemistry and targeted mutational analysis. Diagn. Pathol. 11, 27.
< , E., Bao, F., de Gonzalez, A. K., Moreira, R. K., Lagana, S., Sireci, A. N., Sepulveda, A. R., Remotti, H., Lefkowitch, J. H., Salomao, M. (https://doi.org/10.1186/s13000-016-0475-5>
21. 2003) β-catenin antisense studies in embryonic liver cultures: role in proliferation, apoptosis, and lineage specification. Gastroenterology 124, 202-216.
< , S. P., Monga, H. K., Tan, X., Mule, K., Pediaditakis, P., Michalopoulos, G. K. (https://doi.org/10.1053/gast.2003.50000>
22. 2006) Hepatic adenomas: presumed innocent until proven to be β-catenin mutated. Hepatology 43, 401-404.
< , S. P. (https://doi.org/10.1002/hep.21110>
23. 2016) The therapeutic potential of targeting the HGF/cMET axis in ovarian cancer. Mol. Diagn. Ther. 20, 199-212.
< , K. (https://doi.org/10.1007/s40291-016-0201-8>
24. 2016) Promising new strategies for hepatocellular carcinoma. Hepatol. Res. 47, 251-265.
< , Y. (https://doi.org/10.1111/hepr.12795>
25. 2003) Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 3, 347-361.
< , S., Michieli, P., Galluzzo, M., Mazzone, M., Giordano, S., Comoglio, P. M. (https://doi.org/10.1016/S1535-6108(03)00085-0>
26. 2016) Profile of tivantinib and its potential in the treatment of hepatocellular carcinoma: the evidence to date. J. Hepatocell. Carcinoma 3, 69-76.
< , D., Pyrsopoulos, N. (https://doi.org/10.2147/JHC.S106072>
27. 2007) HNF1α inactivation promotes lipogenesis in human hepatocellular adenoma independently of SREBP-1 and carbohydrate-response elementbinding protein (ChREBP) activation. J. Biol. Chem. 282, 14437-14446.
< , S., Imbeaud, S., Balabaud, C., Boulanger, V., Bertrand-Michel, J., Terce, F., Auffray, C., Bioulac-Sage, P., Zucman-Rossi, J. (https://doi.org/10.1074/jbc.M610725200>
28. 2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumours. Nature 457, 200-204.
< , S., Amessou, M., Couchy, G., Poussin, K., Imbeaud, S., Pilati, C., Izard, T., Balabaud, C., Bioulac-Sage, P., Zucman-Rossi, J. (https://doi.org/10.1038/nature07475>
29. 2004) Hepatocyte nuclear factor-1α gene inactivation: cosegregation between liver adenomatosis and diabetes phenotypes in two maturity-onset diabetes of the young (MODY)3 families. J. Clin. Endocrinol. Metab. 89, 1476-1480.
< , Y., Dao, T., Coutant, R., Chiche, L., Jeannot, E., Clauin, S., Rousselot, P., Fabre, M., Oberti, F., Fatome, A., Zucman-Rossi, J., Bellanne-Chantelot, C. (https://doi.org/10.1210/jc.2003-031552>
30. 2013) A Phase-1b study of tivantinib (ARQ 197) in adult patients with hepatocellular carcinoma and cirrhosis. Br. J. Cancer 108, 21-24.
< , A., Simonelli, M., Rodriguez-Lope, C., Zucali, P., Camacho, L. H., Granito, A., Senzer, N., Rimassa, L., Abbadessa, G., Schwartz, B., Lamar, M., Savage, R. E., Bruix, J. (https://doi.org/10.1038/bjc.2012.556>
31. 2014) Histopathology of hepatocellular carcinoma. World J. Gastroenterol. 20, 15955-15964.
< , M., Terracciano, L. M., D’Angelo, S., Sorrentino, P. (https://doi.org/10.3748/wjg.v20.i43.15955>
32. 2009) Frequent in-frame somatic deletions activate gp130 in inflammatory hepatocellular tumors. Hepatology 49, 1387-1389.
< , M. M., Trautwein, C. (https://doi.org/10.1002/hep.22902>
33. 1994) Expression of the c-met protooncogene in human hepatocellular carcinoma. Hepatology 20, 1231-6.
< , K., Hayashi, N., Yamada, Y., Toshihara, H., Miyamoto, Y., Ito, Y., Ito, T., Katayama, K., Sasaki, Y., Ito, A., Kisida, Y., Kashiwagi, T., Fusamoto, H., Kamada, T. (https://doi.org/10.1002/hep.1840200520>
34. 2008) Different mechanisms of DEHP-induced hepatocellular adenoma tumorigenesis in wild-type and Pparα-null mice. J. Occup. Health 50, 169-180.
< , K., Ito, Y., Gonzalez, F. J., Nakajima, T. (https://doi.org/10.1539/joh.L7105>
35. 1997) Diverse tumorigenesis associated with aberrant development in mice overexpressing hepatocyte growth factor/scatter factor. Proc. Natl. Acad. Sci. USA 94, 701-706.
< , H., LaRochelle, W. J., Sharp, R., Otsuka, T., Kriebel, P., Anver, M., Aaronson, S. A., Merlino, G. (https://doi.org/10.1073/pnas.94.2.701>
36. 2001) Examination of oncogene amplification by genomic DNA microarray in hepatocellular carcinomas: comparison with comparative genomic hybridization analysis. Cancer Genet. Cytogenet. 130, 127-132.
< , S., Arai, H., Kusano, N., Harada, T., Furuya, T., Kawauchi, S., Oga, A., Hirano, T., Yoshida, T., Okita, K., Sasaki, K. (https://doi.org/10.1016/S0165-4608(01)00479-4>
37. 2012) Molecular targeted therapies in hepatocellular carcinoma. Semin. Oncol. 39, 486-492.
< , S., Arii, S. (https://doi.org/10.1053/j.seminoncol.2012.05.005>
38. 2000) u-PA and c-MET mRNA expression is co-ordinately enhanced while hepatocyte growth factor mRNA is down-regulated in human hepatocellular carcinoma. Int. J. Cancer 87, 644-649.
< , D., De Petro, G., Benetti, A., Portolani, N., Giulini, S. M., Barlati, S. (https://doi.org/10.1002/1097-0215(20000901)87:5<644::AID-IJC4>3.0.CO;2-W>
39. 2013) Tivantinib in hepatocellular carcinoma. Expert Opin. Investig. Drugs 22, 141-147.
< , J., Zeuzem, S. (https://doi.org/10.1517/13543784.2013.741586>
40. 2004) Immunohistochemical expression of HGF, c-MET and transcription factor STAT3 in colorectal tumors. Eur. J. Histochem. 48, 291-297.
, M., Vitarelli, E., Grosso, M., Alesci, S., Benvenga, S., Trimarchi, F., Barresi, G. (
41. 2007) Nuclear β-catenin staining and absence of steatosis are indicators of hepatocellular adenomas with an increased risk of malignancy. Histopathology 51, 855-856.
< , S., Libbrecht, L., Katoonizadeh, A., Aerts, R., Nevens, F., Verslype, C., Roskams, T. A. (https://doi.org/10.1111/j.1365-2559.2007.02862.x>
42. 2016) Better to be alone than in bad company: the antagonistic effect of cisplatin and crizotinib combination therapy in non-small cell lung cancer. World J. Clin. Oncol. 7, 425-432.
< , N., Deben, C., Deschoolmeester, V., Wouters, A., Lardon, F., Rolfo, C., Germonpre, P., Giovannetti, E., Peters, G. J., Pauwels, P. (https://doi.org/10.5306/wjco.v7.i6.425>
43. 2013) Genomic landscape of copy number aberrations enables the identification of oncogenic drivers in hepatocellular carcinoma. Hepatology 58, 706-717.
< , K., Lim, H. Y., Shi, S., Lee, J., Deng, S., Xie, T., Zhu, Z., Wang, Y., Pocalyko, D., Yang, W. J., Rejto, P. A., Mao, M., Park, C. K., Xu, J. (https://doi.org/10.1002/hep.26402>
44. 2016) Helicobacter pylori upregulates Nanog and Oct4 via Wnt/β-catenin signaling pathway to promote cancer stem cell-like properties in human gastric cancer. Cancer Lett. 374, 292-303.
< , X., Tang, B., Xiao, Y. F., Xie, R., Qin, Y., Luo, G., Hu, C. J., Dong, H., Yang, S. M. (https://doi.org/10.1016/j.canlet.2016.02.032>
45. 2006) Genotype-phenotype correlation in hepatocellular adenoma: new classification and relationship with HCC. Hepatology 43, 515-524.
< , J., Jeannot, E., Nhieu, J. T., Scoazec, J. Y., Guettier, C., Rebouissou, S., Bacq, Y., Leteurtre, E., Paradis, V., Michalak, S., Wendum, D., Chiche, L., Fabre, M., Mellottee, L., Laurent, C., Partensky, C., Castaing, D., Zafrani, E. S., Laurent-Puig, P., Balabaud, C., Bioulac-Sage, P. (https://doi.org/10.1002/hep.21068>
46. 2008) Human and mouse hepatocellular adenoma and carcinoma display similar tumorigenesis pathway alterations. J. Hepatol. 48, 884-886.
< , J. (https://doi.org/10.1016/j.jhep.2008.02.001>